SYNMOSA BIOPHARMA CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.55 TWD | +1.15% |
|
+2.06% | +2.33% |
| Sales 2022 | 4.39B 135M 10.79B | Sales 2023 | 5.14B 159M 12.65B | Capitalization | 14.71B 454M 36.19B |
|---|---|---|---|---|---|
| Net income 2022 | 799M 24.64M 1.97B | Net income 2023 | 595M 18.35M 1.46B | EV / Sales 2022 | 4.09 x |
| Net Debt 2022 | 1.94B 59.75M 4.77B | Net Debt 2023 | 783M 24.13M 1.93B | EV / Sales 2023 | 3.01 x |
| P/E ratio 2022 |
19.9
x | P/E ratio 2023 |
24
x | Employees | - |
| Yield 2022 |
1.14% | Yield 2023 |
1.55% | Free-Float | 77.3% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.15% | ||
| 1 week | +2.06% | ||
| Current month | +2.59% | ||
| 1 month | +0.38% | ||
| 3 months | +5.61% | ||
| 6 months | +6.89% | ||
| Current year | +2.33% |
1 week
38.80
39.60
1 month
37.5039.60
Current year
36.9540.50
1 year
34.9043.70
3 years
17.4551.06
5 years
10.4251.06
10 years
10.4251.06
| Managers | Title | Age | Since |
|---|---|---|---|
Chih Hui Lin
CEO | Chief Executive Officer | - | 25/08/70 |
Hung Chin Pai
DFI | Director of Finance/CFO | - | 31/03/01 |
Sheng Jen Yang
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chih Hui Lin
CEO | Chief Executive Officer | - | 25/08/70 |
Wan Ju Liao
BRD | Director/Board Member | 41 | 23/05/19 |
Li Wen Huang
BRD | Director/Board Member | 51 | 23/05/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 39.55 | +1.15% | 1,277,333 |
| 09/05/24 | 39.1 | -0.76% | 911,045 |
| 08/05/24 | 39.4 | +0.77% | 1,026,251 |
| 07/05/24 | 39.1 | 0.00% | 663,054 |
| 06/05/24 | 39.1 | +0.90% | 880,808 |
End-of-day quote Taipei Exchange, May 09, 2024
More quotes
SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.33% | 465M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 4114 Stock
